Article Information
History
- August 22, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Andrii Rabets1,
- Galyna Bila1,
- Roman Grytsko1,
- Markian Samborsky2,
- Yuriy Rebets2,
- Sandor Vari3,
- Quentin Pagneux4,
- Alexandre Barras4,
- Rabah Boukherroub4,
- Sabine Szunerits4 and
- Rostyslav Bilyy1,*
- 1Danylo Halytsky Lviv National Medical University, Pekarska str, 69, 79010 Lviv, Ukraine
- 2Explogen LLC, Zelena Str. 20, Lviv, 79005, Ukraine
- 3International Research and Innovation in Medicine Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- 4Univ. Lille, CNRS, Centrale Lille, Univ. Polytechnique Hauts-de-France, UMR 8520 - IEMN, F-59000 Lille, France
- ↵*to whom correspondence should be send to: r.bilyy{at}gmail.com (RB)
Posted August 22, 2020.
Development of antibodies to pan-coronavirus spike peptides in convalescent COVID-19 patients
